Quick Answer
Vanda Pharmaceuticals Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $216.11 million for the year ending 2025.
- Vanda Pharmaceuticals Inc. showed an increase of +8.7% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from Vanda Pharmaceuticals Inc.'s annual report (Form 10-K), filed with the SEC on February 12, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 10 years of available data (2016 to 2025), Vanda Pharmaceuticals Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 48.0%.
- Historical annual values: Fiscal year 2025: $216.11 million | Fiscal year 2024: $198.77 million | Fiscal year 2023: $192.64 million | Fiscal year 2022: $254.38 million | Fiscal year 2021: $268.68 million | Fiscal year 2020: $248.17 million | Fiscal year 2019: $227.19 million | Fiscal year 2018: $193.12 million | Fiscal year 2017: $165.08 million | Fiscal year 2016: $146.02 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: